<i>Stenotrophomonas maltophilia</i> Infections in Haematological Malignancies and Hematopoietic Stem Cell Transplantation: A Case Series including Cefiderocol-Based Regimens
Tommaso Lupia,
Fabrizio Carnevale-Schianca,
Davide Vita,
Alessandro Busca,
Daniela Caravelli,
Elena Crisà,
Vanesa Gregorc,
Antonio Curtoni,
Alessandro Cerutti,
Nour Shbaklo,
Silvia Corcione,
Francesco Giuseppe De Rosa
Affiliations
Tommaso Lupia
Unit of Infectious Diseases, Cardinal Massaia, 14100 Asti, Italy
Fabrizio Carnevale-Schianca
Unit of Oncology and Haematology, Candiolo Cancer Institute, FPO-IRCCS Strada Provinciale 142, 10060 Candiolo, Italy
Davide Vita
Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy
Alessandro Busca
Department of Oncology, Stem Cell Transplant Center, Città della Salute e della Scienza Hospital, 10100 Turin, Italy
Daniela Caravelli
Unit of Oncology and Haematology, Candiolo Cancer Institute, FPO-IRCCS Strada Provinciale 142, 10060 Candiolo, Italy
Elena Crisà
Unit of Oncology and Haematology, Candiolo Cancer Institute, FPO-IRCCS Strada Provinciale 142, 10060 Candiolo, Italy
Vanesa Gregorc
Unit of Oncology and Haematology, Candiolo Cancer Institute, FPO-IRCCS Strada Provinciale 142, 10060 Candiolo, Italy
Antonio Curtoni
Microbiology and Virology Unit, University Hospital Città della Salute e della Scienza di Torino, 10100 Turin, Italy
Alessandro Cerutti
Intensive Care Unit, IRCCS Candiolo, 10100 Candiolo, Italy
Nour Shbaklo
Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy
Silvia Corcione
Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy
Francesco Giuseppe De Rosa
Unit of Infectious Diseases, Cardinal Massaia, 14100 Asti, Italy
Background and Objectives: Stenotrophomonas maltophilia is a ubiquitous, aerobic, Gram-negative bacillus causing increasing concern in patients affected by haematological malignancies. Materials and Methods: We report a case series from two centres in Northern Italy to describe the characteristics, outcome and microbiological response of S. maltophilia infections in patients with haematological malignancies and/or allogenic hematopoietic stem cell transplantation (aHSCT). Results: Ten patients were included. The median age was 67 years, and seven patients (70%) were males. The median Charlson Comorbidity Index was 6 (IQR: 4–8). The most frequent haematological comorbidities were acute myeloid leukaemia (AML; n = 3; 30%) and non-Hodgkin’s lymphoma (n = 3; 30%). Three (30%) patients underwent aHSCT before infection, all for AML. All the patients had undergone a recent antibiotics course and had an indwelling central venous catheter before infection. The main clinical presentations were nosocomial pneumonia, with (2; 20%) or without (4; 40%) secondary bloodstream infection and CRBSI (3; 30%). Four patients were treated with cefiderocol in monotherapy or combinations therapy with cotrimoxazole. The rest of the patients were treated with cotrimoxazole or levofloxacin in monotherapy. Conclusions: Despite a high rate of clinical improvement (90%) after starting antimicrobial therapy, we faced high 30-day mortality (30%) and in-hospital mortality (50%) rates in a highly comorbid population.